Statine nella tempesta

(articolo pubblicato sul sito il 28 aprile 2014)

References

1. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd-Jones DM, Blum CB, McBride P, Eckel RH, Schwartz JS, Goldberg AC, Shero ST, Gordon D, Smith SC Jr, Levy D, Watson K, Wilson PW. J Am Coll Cardiol. 2013 Nov 7. pii: S0735-1097(13)06028-2. doi: 10.1016/j.jacc.2013.11.002. [Epub ahead of print] No abstract available. 
2. Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 American College of Cardiology/American Heart Association cholesterol guideline.  Stone NJ, Robinson JG, Lichtenstein AH, Goff DC Jr, Lloyd-Jones DM, Smith SC Jr, Blum C, Schwartz JS; 2013 ACC/AHA Cholesterol Guideline Panel. Ann Intern Med. 2014 Mar 4;160(5):339-43. doi: 10.7326/M14-0126

3. risk estimator from the CardioSource Website.

4. Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. Lancet 2013; 382: 1762-1765. Full Text | PDF(535KB) | PubMed

5. Cholesterol Guidelines Under Attack – NYTimes.com 

6. Controversy over clinical guidelines: listen to the evidence, not the noise. Guallar E, Laine C. Ann Intern Med. 2014 Mar 4;160(5):361-2. doi: 10.7326/M14-0112. No abstract available.

7. Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations.  Muntner P, Colantonio LD, Cushman M, Goff DC Jr, Howard G, Howard VJ, Kissela B, Levitan EB, Lloyd-Jones DM, Safford MM.  JAMA. 2014 Apr 9;311(14):1406-15. doi: 10.1001/jama.2014.2630

8. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Ray KK, Kastelein JJ, Matthijs Boekholdt S, Nicholls SJ, Khaw KT, Ballantyne CM, Catapano AL, Reiner Z, Lüscher TF.  Eur Heart J. 2014 Apr;35(15):960-8. doi: 10.1093/eurheartj/ehu107. Epub 2014 Mar 17.
9. Heart Protection Study  Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 360 (2002), pp. 7–22
10. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Study Collaborative Group. Lancet. 2004 Mar 6;363(9411):757-67.
11. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial.  Heart Protection Study  Collaborative Group, Bulbulia R, Bowman L, Wallendszus K, Parish S, Armitage J, Peto R, Collins R.  Lancet. 2011 Dec 10;378(9808):2013-20. doi: 10.1016/S0140-6736(11)61125-2. Epub 2011 Nov 22.